
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rfviii-Fc
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study
Details : Rfviii-Fc is a Protein-drug Conjugate drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemophilia A.
Product Name : Undisclosed
Product Type : Protein-drug Conjugate
Upfront Cash : Inapplicable
November 18, 2023
Lead Product(s) : Rfviii-Fc
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eptacog Alfa is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hemophilia A.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 10, 2021
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eptacog Alfa is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemophilia A.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 02, 2019
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Trastuzumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 07, 2018
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Denosumab
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Denosumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoporosis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 26, 2017
Lead Product(s) : Denosumab
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bevacizumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Bevacizumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 20, 2017
Lead Product(s) : Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Etanercept
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetic, Safety and Tolerability Study of Altebrel in Healthy Male Subjects
Details : Etanercept is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 06, 2017
Lead Product(s) : Etanercept
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eptacog Alfa is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Factor VII Deficiency.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 14, 2017
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
